Dermovate

How to order Dermovate

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Dermovate on Prescriptsy

Dermovate is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Dermovate contains clobetasol propionate 0.05%, the most potent topical corticosteroid available in the United Kingdom.

It is classified as very potent (Group IV in the UK four-group system) and is licensed for the short-term treatment of severe, resistant inflammatory skin conditions that have not responded to less potent corticosteroids.

These include recalcitrant eczema (atopic dermatitis), psoriasis of the palms and soles, hypertrophic lichen planus, discoid lupus erythematosus, and other severe dermatoses.

Due to its exceptional potency, Dermovate carries the highest risk of local and systemic adverse effects among topical corticosteroids and should be reserved for situations where milder options have proved insufficient.

Inflammatory skin conditions affect millions of people in the UK. Eczema alone affects around 1 in 5 children and 1 in 10 adults.

While the majority of cases respond to emollients and mild to moderate topical corticosteroids, a significant minority develop severe, treatment-resistant disease that causes substantial pain, sleep disturbance, and psychological distress.

For these patients, a short, carefully monitored course of a very potent corticosteroid such as Dermovate can provide rapid relief when other treatments have been exhausted.

This page provides a comprehensive clinical overview of how Dermovate works, who it is suitable for, correct application, expected benefits, side effects, safety warnings, and how to obtain a prescription in the UK.

Important safety information about Dermovate

Before reading further, note the following essential safety points. Dermovate is a prescription-only medicine (POM) and must only be used under medical supervision.

• Dermovate is the most potent topical corticosteroid available. Use the minimum amount for the shortest effective time, normally no longer than 4 consecutive weeks.
• Do not use on the face, groin, or axillae unless under specialist supervision. These areas are highly susceptible to corticosteroid-induced skin thinning and other side effects.
• Do not exceed 50 g per week. Excessive use increases the risk of systemic absorption and adrenal suppression.
• Do not stop Dermovate abruptly after prolonged use. Gradual dose reduction is recommended to avoid rebound flare.
• Do not apply to untreated infections. Corticosteroids can mask and worsen bacterial, fungal, and viral skin infections.

Understanding very potent topical corticosteroids

Topical corticosteroids are classified by potency in the UK using a four-group system: mild (Group I, such as hydrocortisone 1%), moderate (Group II, such as clobetasone butyrate), potent (Group III, such as betamethasone valerate 0.1%), and very potent (Group IV, such as clobetasol propionate 0.05%).

Potency reflects the degree of anti-inflammatory effect and, correspondingly, the risk of adverse effects.

Very potent corticosteroids produce the greatest therapeutic effect but also carry the greatest potential for harm, which is why they are reserved as a final step in the topical corticosteroid ladder.

The choice of potency depends on the severity, site, and chronicity of the condition. Mild preparations are suitable for the face, flexures, and children's skin.

Moderate and potent preparations are used for moderate disease on the trunk and limbs.

Very potent preparations like Dermovate are reserved for severe, thickened, or resistant lesions, typically on the palms, soles, scalp, or trunk, and almost never on the face or flexures.

How Dermovate works: mechanism of action

Clobetasol propionate exerts its anti-inflammatory effect through a well-characterised intracellular pathway. After crossing the cell membrane, it binds to the glucocorticoid receptor in the cytoplasm.

The activated receptor-steroid complex translocates to the nucleus, where it binds to glucocorticoid response elements (GREs) on DNA and modulates the transcription of a wide range of genes involved in the inflammatory cascade.

Key anti-inflammatory effects include suppression of pro-inflammatory cytokines (interleukin-1, interleukin-6, tumour necrosis factor-alpha), inhibition of phospholipase A2 (reducing prostaglandin and leukotriene synthesis), decreased production of adhesion molecules (reducing leucocyte migration to inflamed sites), reduced capillary permeability (decreasing oedema and erythema), and inhibition of fibroblast proliferation (which contributes to the thinning effect with prolonged use).

Additionally, clobetasol propionate has antipruritic effects through modulation of itch-mediating neuropeptides and immunosuppressive effects by reducing the number and activity of T lymphocytes, mast cells, and Langerhans cells in the treated skin.

These combined actions produce rapid and pronounced relief of the redness, swelling, itching, and scaling that characterise severe inflammatory dermatoses.

Conditions treated with Dermovate

Recalcitrant eczema

Atopic eczema is a chronic, relapsing inflammatory skin condition driven by immune dysregulation and barrier dysfunction.

Most cases respond to emollients, mild or moderate topical corticosteroids, and trigger avoidance.

However, some patients develop severe, widespread, or thickened eczema that fails to respond to these first-line measures.

In these cases, short courses of Dermovate applied to the worst-affected areas can break the itch-scratch cycle, reduce inflammation, and restore the skin barrier sufficiently for maintenance with less potent preparations.

Psoriasis

Psoriasis is a chronic immune-mediated condition characterised by well-demarcated, erythematous, scaly plaques. Dermovate is used for localised, thick, treatment-resistant plaques, particularly on the palms, soles, and scalp.

It should not be used for widespread psoriasis due to the quantity required and the risk of rebound or pustular transformation on withdrawal.

Psoriasis management typically involves a combination of topical treatments (corticosteroids, vitamin D analogues, tar-based preparations), phototherapy, and systemic agents for more severe disease.

Lichen planus

Lichen planus is an inflammatory condition presenting as flat-topped, violaceous, polygonal papules, often intensely itchy. Hypertrophic lichen planus, which produces thickened, resistant plaques, may require very potent corticosteroids for adequate control. Dermovate can be highly effective for localised hypertrophic disease.

Discoid lupus erythematosus

Discoid lupus is a chronic autoimmune condition causing well-defined, scaly, erythematous plaques that can lead to scarring and pigment changes.

Very potent topical corticosteroids are a standard first-line treatment for localised disease. Dermovate helps suppress the immune-mediated inflammation and reduce the risk of permanent scarring.

Dosage and application

Apply Dermovate cream or ointment thinly to the affected area once or twice daily.

Use the fingertip unit (FTU) method to gauge the correct amount: one FTU (approximately 0.5 g, the amount squeezed from a standard tube from the tip of an adult finger to the first crease) covers an area of skin equal to two flat adult palms.

Apply only to affected skin, avoiding healthy surrounding areas.

Treatment should not normally exceed 4 consecutive weeks. Do not use more than 50 g per week.

If no improvement is seen within 2 to 4 weeks, the diagnosis should be reassessed.

Once the condition has responded adequately, step down to a less potent corticosteroid for ongoing maintenance.

A gradual tapering strategy, such as reducing application to alternate days and then to twice weekly before switching to a moderate preparation, helps minimise the risk of rebound flare.

Choose the cream formulation for moist, weeping, or acutely inflamed skin and the ointment for dry, scaly, thickened, or hyperkeratotic lesions. The ointment provides better occlusion and hydration, which can enhance efficacy but also increases absorption.

Side effects of Dermovate

Local side effects

Burning, stinging, or itching at the application site may occur initially and usually settles quickly.

The most clinically significant local side effects result from prolonged or inappropriate use and include skin thinning (atrophy), stretch marks (striae), visible surface blood vessels (telangiectasia), easy bruising (purpura), delayed wound healing, altered pigmentation, and increased fine hair growth.

On the face, steroid rosacea and perioral dermatitis are recognised complications. Striae, once established, are generally permanent.

Systemic side effects

Significant systemic absorption can occur with extensive application, prolonged use, occlusion, or application to damaged skin.

Systemic effects include suppression of the hypothalamic-pituitary-adrenal axis (presenting as fatigue, dizziness, nausea, and in severe cases, adrenal crisis on withdrawal), Cushingoid features, hyperglycaemia, and osteoporosis with very prolonged high-dose use.

Children are at increased risk of systemic absorption due to their higher body surface area to body weight ratio, and growth suppression has been reported.

Psoriasis-specific risks

In patients with psoriasis, abrupt withdrawal of potent topical corticosteroids can trigger a severe rebound flare.

Rarely, generalised pustular psoriasis can develop, which is a medical emergency requiring hospital admission. This risk underlines the importance of supervised tapering and careful patient selection.

When to seek medical advice

Contact your GP or dermatologist if you notice skin thinning, persistent stretch marks, unusual bruising, signs of skin infection (increased redness, warmth, pus), or any worsening of your condition.

Report suspected adverse reactions via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk .

Warnings and precautions

Sites to avoid

Do not apply Dermovate to the face, eyelids, groin, axillae, or genital area except under specialist dermatological supervision.

These sites have thinner skin and greater absorption, substantially increasing the risk of atrophy, striae, telangiectasia, and, around the eyes, glaucoma and cataracts.

Infections

Do not apply Dermovate to untreated bacterial, fungal, or viral infections. Corticosteroids suppress local immunity and can mask clinical signs of infection while allowing it to spread.

If infection is present or suspected, appropriate antimicrobial treatment should be initiated first or concurrently.

Occlusive dressings

Do not use Dermovate under occlusive dressings unless specifically directed by a dermatologist. Occlusion dramatically increases percutaneous absorption and the risk of both local and systemic side effects.

If occlusion is deemed necessary (for example, for thick palmar psoriasis), it should be under close specialist supervision with treatment limited to a few days.

Children

Dermovate should be prescribed for children only by or on the advice of a dermatologist. Use the smallest effective amount for the shortest time. Monitor growth in children requiring repeated courses of potent topical corticosteroids.

Pregnancy and breastfeeding

Use Dermovate with caution during pregnancy, particularly in the first trimester. Apply to the smallest area for the shortest duration. Avoid extensive or prolonged use.

It is not known whether clobetasol propionate is excreted in breast milk; avoid application to the breast area during breastfeeding.

Stepping down from Dermovate

Dermovate is intended as a short-term rescue treatment, not a long-term maintenance therapy. Once the acute flare has been controlled, your prescriber should plan a step-down strategy.

This typically involves reducing the frequency of Dermovate application (from daily to alternate days to twice weekly) before switching to a potent (Group III) or moderate (Group II) corticosteroid for maintenance.

Emollients should be continued throughout and remain the foundation of ongoing skin care.

For conditions that flare frequently, a proactive maintenance approach (sometimes called "weekend therapy") may be recommended, using a moderate or potent corticosteroid twice weekly on previously affected areas to prevent relapse, combined with regular emollient use.

How to get a Dermovate prescription in the UK

Dermovate is a prescription-only medicine. It should be prescribed only after an appropriate clinical assessment, usually by a GP with dermatological experience or a dermatologist.

New prescriptions are typically initiated when the prescriber has confirmed the diagnosis, documented the failure of less potent corticosteroids, and discussed the risks and benefits with the patient.

The standard NHS prescription charge in England is currently 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

When to seek medical advice

Contact your GP or dermatologist if your condition does not improve within 2 to 4 weeks, if it worsens despite treatment, if you notice signs of skin thinning or stretch marks, or if you develop new symptoms.

Seek urgent medical advice if you develop widespread pustular rash, signs of skin infection, or if you feel unwell after stopping Dermovate.

Report all suspected adverse reactions via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk .

Sources

• Dermovate Cream, Summary of Product Characteristics (EMC)
• Clobetasol propionate, British National Formulary (BNF)
• NICE CKS: Corticosteroids, topical
• Topical steroids, NHS
• British Association of Dermatologists, Topical Steroids
• MHRA Yellow Card Scheme